Clinical Trials


Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

This study has been completed

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: December 1999
History of Changes


The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.

Condition Intervention
Candidiasis, Oral
HIV Infections

Drug : Terbinafine hydrochloride

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Four-Week, Open-Label, Non-Randomized, Multicenter, Dose-Finding, Pilot Study to Evaluate the Safety and Efficacy of Two Daily Doses of Lamisil (1500 Mg and 2000 Mg), Administered for a Maximum of 4 Weeks in HIV-Positive Subjects With Oral Mucosal Candidiasis Not Having Responded to a Minimum of 200 Mg Fluconazole Monotherapy

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 30

Detailed Description:

This is an open-label, dose-escalating study with up to 2 sequential cohorts. The first 15 patients receive Lamisil for 2 weeks. After 2 weeks, patients considered clinically cured (i.e., absence of removable, white plaques) are removed from treatment; patients not considered clinically cured receive an additional 2 weeks of treatment. At the end of 4 weeks, treatment is discontinued, regardless of clinical cure outcome. If less than 80% of patients are clinically cured after the 4 weeks of treatment, a second cohort of 15 patients receive Lamisil on the same treatment regimen as first cohort (i.e., initial 2-week treatment period, with an additional 2 weeks of treatment for those patients who are not considered clinically cured after 2 weeks of treatment).



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
You may be eligible for this study if you:

  • Are at least 18 years old.
  • Have thrush that has not responded to at least 10 days of fluconazole treatment.
  • Are HIV-positive.
  • Are expected to live at least 4 weeks.
  • Are able to take oral medication.

  • Exclusion Criteria
    You will not be eligible for this study if you:
  • Have liver or kidney disease.
  • Have received certain medications.
  • Have a history of serious diarrhea or digestive problems.
  • Are pregnant or breast-feeding.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002394


United States, Florida
Therafirst Med Ctr
Fort Lauderdale, Florida, United States, 33308
Associates in Research
Fort Myers, Florida, United States, 33901
Clireco Inc
Tamarac, Florida, United States, 33321
Infectious Diseases Research Inc
Tampa, Florida, United States, 33614
United States, Illinois
Northwestern Univ / Division of Infectious Disease
Chicago, Illinois, United States, 60611
United States, New Jersey
Saint Michaels Med Ctr / Infectious Disease Resch Dpt
Newark, New Jersey, United States, 071029880
United States, New York
St Vincents Hosp / Clinical Research Program
New York, New York, United States, 10011
United States, Texas
Univ of Texas Med Branch
Galveston, Texas, United States, 77555
United States, Virginia
Hampton Roads Med Specialists
Hampton, Virginia, United States, 23666

Sponsors and Collaborators

More Information

More Information

Responsible Party: Novartis Identifier: NCT00002394   History of Changes  
Other Study ID Numbers: 282A  
  SFS 257-E-00  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

AIDS-Related Opportunistic Infections
Dose-Response Relationship, Drug
Antifungal Agents
Candidiasis, Oral
Drug Administration Schedule

Additional relevant MeSH terms:
HIV Infections
Candidiasis, Oral
Terbinafine processed this data on September 21, 2018
This information is provided by